Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-12 peptide vaccine
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
MAGE-12 peptide vaccine is a synthetic therapeutic cancer vaccine designed to stimulate the immune system to target tumor cells expressing the melanoma-associated antigen gene family member A12 (MAGEA12). The vaccine contains a shared tumor antigen epitope recognized by tumor-infiltrating lymphocytes (TILs), and its administration aims to induce a TIL response against MAGE-12-expressing tumors, potentially resulting in decreased tumor growth. It has been developed primarily for use in patients with cancers that express the MAGE-12 antigen, including various solid tumors. The National Cancer Institute is the originator and primary developer of this investigational agent[1][2].
02
Targets
HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)MAGEA12 (Melanoma-associated antigen family A member 12)
Beyond the preview
Go deeper on MAGE-12 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-12 peptide vaccine.